Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey

Cobanoglu N., Ozcelik U., ÇAKIR E., ŞİŞMANLAR EYÜBOĞLU T., PEKCAN S., Cinel G., ...Daha Fazla

PEDIATRIC PULMONOLOGY, cilt.55, sa.9, ss.2302-2306, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 55 Sayı: 9
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1002/ppul.24854
  • Dergi Adı: PEDIATRIC PULMONOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.2302-2306
  • Anahtar Kelimeler: cystic fibrosis, modulator drugs, national registry, TEZACAFTOR-IVACAFTOR
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Background A better understanding of cystic fibrosis transmembrane conductance regulator biology has led to the development of modulator drugs such as ivacaftor, lumacaftor-ivacaftor, tezacaftor-ivacaftor, and elexacaftor-tezacaftor-ivacaftor. This cross-sectional study evaluated cystic fibrosis (CF) patients eligible for modulator drugs.